Stuart M. Cable

Stuart M. Cable

Partner Chair, M&A and Corporate Finance Tech | Life Sciences
Stuart M. Cable


Stuart Cable represents as outside general counsel public and private companies involved in the life sciences and technology sectors.

He currently serves as the chair of the M&A and Corporate Finance practices for the firm’s Technology and Life Sciences business units. He previously served as chair of the firm’s Corporate Department, as chair of its Hiring Committee, as chair of its Incubator, and as a member of the firm's Executive and Allocations Committees.

Areas of Practice
TÄTIGKEITSFELDER
Domaines D’Expertise
业务范围

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Mr. Cable counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters.

Mr. Cable represents buyers, sellers and investment banks in his M&A practice. Representative M&A transactions include the sale of Onyx Pharmaceuticals to Amgen ($10.4 billion), the sale of Eloqua to Oracle ($1 billion), the sale of Idenix to Merck ($3.8 billion), the sale of Pharmacyclics to AbbVie ($21 billion), the sale of Xoom to PayPal ($1 billion), the private company sale of Stemcentrix to Abbvie ($5.8 billion), the sale of Opower to Oracle ($600 million), the abandoned acquisition of NXP by Qualcomm ($47 billion), the Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion), the cross border private company acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain) by AMRI, the acquisition of Auspex by Teva Pharmaceuticals ($3.5 billion), the 2017 sale of Neustar to Golden Gate ($2.9 billion), the 2017 sale of Lionbridge to HIG ($400 million), the 2017 sale of AMRI to Carlyle and GTCR ($1.9 billion), the 2017 sale of PAREXEL to Pamplona ($5 billion), the private company acquisition and subsequent 2018 sale of Cord Blood Registry by AMAG Pharmaceuticals, the 2018 cross border sale of inviCRO to Konica Minolta (Japan) ($300 million), the  majority sale of Foundation Medicine to Roche ($1 billion) and the subsequent (2018) negotiated tender for the public stub by Roche ($2.4 billion), the 2018 merger of equals transaction between Keryx and Akebia ($1 billion), the 2019 acquisition of Civitas by Centerbridge ($1.4 billion) and the 2019 sale of Spark to Roche ($4.8 billion).

Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors, most recently representing the independent committee of the Board of Directors of Sprint in the pending 2018 Sprint/T-Mobile transaction ($26 billion). In the course of his career, Mr. Cable has negotiated and executed over 300 M&A transactions.

Mr. Cable serves regularly as counsel to issuers in IPOs, most recently representing Moderna and Rubius in their record setting IPOs in the biotechnology industry. Mr. Cable also represents underwriters in such transactions, including Morgan Stanley, JPM and Citi.

Mr. Cable represents tech and life sciences companies in complex minority strategic transactions including KIND in its 2018 partnership with Mars, Cornerstone onDemand in its 2018 $300 million convertible debt PIPE with Silver Lake and Microsoft, and PTC in its 2018 $1 billion common stock PIPE and strategic partnership with Rockwell.

Mr. Cable periodically represents public companies in connection with highly confidential “activist” matters, including the successful negotiation of "Cooperation" Agreements with Elliott Management on behalf of Cognizant and Citrix.

Mr. Cable also represents a number of life sciences and technology companies as outside general counsel, including AMAG, Citrix, Cogen, Corbus, Integral, Moderna, Novelion, Ohana, PAREXEL, PTC, Rubius, Shields Healthcare Solutions and Yumanity. Mr. Cable also represents the health care delivery start-up founded by Amazon, Berkshire Hathaway and J.P. Morgan and led by Atul Gawande.

COMMUNITY AND PRO BONO ACTIVITIES

Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College, as chairman emeritus of the Buckingham Browne & Nichols School and as a member of the Board of the Irving Institute for Engineering and Science at Dartmouth College. He also served for more than a decade as a member of the Board of Fellows of Harvard Medical School.

Mr. Cable leads the firm’s Pro Bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth founded by Jack Connors.

Mr. Cable is also a member of the Goodwin Pro Bono team servicing the Boston Red Sox Foundation where Mr. Cable advises on Board and governance matters.

Recognition

Mr. Cable is annually ranked in Chambers USA: America’s Leading Lawyers for Business (Corporate/M&A – Band 1), Chambers Global: The Leading Lawyers for Business (Corporate/M&A) and U.S. News-Best Lawyers (Corporate Law). Global M&A Network has named him one of the world’s top 50 M&A lawyers, recognizing his work advising Onyx Pharmaceuticals in its $10.4 billion purchase by Amgen – a transaction named 2014 Global Major Markets Life Sciences Deal of the Year. Mr. Cable also was recognized by the Financial Times in both 2015 and 2016, winning its award for Innovative Deal of the Year in advising Foundation Medicine in its $1 billion majority purchase by Roche, and in 2016 advising Citrix in its $2.6 billion Reverse Morris Trust merger with LogMeIn. In 2016, Mr. Cable was recognized by LMG as Life Sciences Transaction Attorney of the Year. In 2017, Mr. Cable was recognized by Law360 as Life Sciences MVP.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 1979
Columbia Law School

(Harlan Fiske Stone Scholar)

M.B.A., 1976
Tuck School of Business at Dartmouth
A.B., 1975
Dartmouth College

(magna cum laude)

Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师